Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00771108
Other study ID # 06-0039
Secondary ID #5P30 DK052574 (
Status Completed
Phase N/A
First received October 9, 2008
Last updated September 2, 2011
Start date May 2006
Est. completion date April 2011

Study information

Verified date September 2011
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people. NAFLD, which is common in obese people, occurs when the liver has too much fat.


Description:

Non-alcoholic fatty liver disease (NAFLD) affects about 33% of adults in the United States. The prevalence of NAFLD is four to five times higher in obese than lean persons and is associated with insulin resistance and the metabolic syndrome. Decreasing calorie intake and increasing physical activity has been recommended as primary therapy for NAFLD, but the independent effect of aerobic exercise is unknown. The current exercise guidelines for disease prevention and weight management range from 150 min/wk, recommended by the Centers for Disease Control and the American College of Sports Medicine, to 300 min/wk, recommended by the Institute of Medicine. However, it is not known whether aerobic exercise alone can improve NAFLD, and which recommended dose of exercise might have the most beneficial effects. The purpose of this proposal is to determine the effect of moderate intensity endurance exercise on: 1) hepatic fat content; 2) hepatic lipoprotein kinetics; and 3) plasma inflammatory markers. We hypothesize that aerobic exercise will decrease hepatic fat content, improve VLDL kinetics, and decrease inflammation in a dose-dependent fashion. The results from this study will help determine exercise guidelines for obese patients with NAFLD, and lay the groundwork for future studies evaluating the effects of exercise on metabolic diseases associated with obesity.

This proposal involves conducting a randomized controlled trial that will randomize obese subjects with NAFLD (> 10% hepatic fat content) to one of two groups: Group 1 (Control, no exercise) and Group 2 (Moderate Intensity Aerobic Exercise- 150 min/wk to 300 min/wk of supervised exercise performed at 45-55% of O2 max).


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date April 2011
Est. primary completion date April 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age 18-65 with Nonalcoholic Fatty Liver Disease as determined by MRS

Exclusion Criteria:

- Medical History

- Diabetes

- Heart Disease

- Asthma/Lung disease

- Injury that prevents exercise

- Social history

- Drinking

- More than one drink per day

- Binge drinking on the weekends (more than 3 or 4 drinks per weekend day)

- Smoking

- It's OK if they were a previous smoker, but they need to have quit more than 6 months ago

- Exercise

- They must exercise less than one hour per week

- Medications: must be on stable regimen of ANY medication for at least 3 months

- Beta-Blockers

- Lipid/cholesterol lowering medications:

- Oral hypoglycemics (anti-diabetes medications - some like metformin are indicated for pre-diabetes)

- Hormone replacement therapy

- If the woman is pre-menopausal, it is OK if she is on birth control as long as she has been on it over 3 months

- Weight history

- Weight <300 lbs

- BMI 30 to 45

- Weight stable - <10lbs weight loss or gain in the last 3 months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Behavioral:
exercise
For 16 weeks subjects will exercise from 30-60 minutes five times a week.

Locations

Country Name City State
United States Washington University School of Medicine St. Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The effect of aerobic exercise on: Intrahepatic fat content 3 years No
Secondary VLDL-triglyceride (TG) and VLDL-Apolipoprotein B (apoB) kinetics 3 years No
Secondary Insulin action in liver (suppression of glucose production), muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis). 3 years No
Secondary Plasma markers of inflammation 3 years No
Secondary Potential cellular mechanisms responsible for changes in insulin action and inflammation 3 years No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04099147 - Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence.
Completed NCT04019561 - A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Phase 2
Withdrawn NCT00375349 - Non Alcoholic Fatty Liver Disease Influence of Statin Therapy N/A
Active, not recruiting NCT04682600 - The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF N/A
Terminated NCT02605616 - Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD) Phase 2
Completed NCT04165343 - Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Recruiting NCT03151473 - Longitudinal Observational Study Of Chinese With NAFLD/NASH
Recruiting NCT04820036 - A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) N/A
Active, not recruiting NCT02037321 - Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk N/A
Completed NCT01997424 - Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus N/A
Completed NCT01110577 - Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171) N/A
Recruiting NCT04639414 - Combined Active Treatment in Type 2 Diabetes With NASH Phase 4
Completed NCT04450875 - Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD N/A
Recruiting NCT02654665 - Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Phase 3
Recruiting NCT05699018 - Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients N/A
Withdrawn NCT02457286 - Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study Phase 1
Withdrawn NCT02194894 - The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients N/A
Completed NCT01811472 - Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients Phase 2
Completed NCT00968747 - Regulation of FGF21 by Nutritional Challenges N/A
Recruiting NCT04330326 - Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease Phase 2